Positive Phase 3 Trial of DUPIXENT(R) (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis

U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 TARRYTOWN, N.Y. and PARIS, May 16, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivo... Biopharmaceuticals, Dermatology Regeneron Pharmaceuticals, Sanofi, DUPIXENT, dupilumab, atopic dermatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news